Nurix therapeutics announces extension of strategic collaboration with gilead sciences
Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licensing fees, and up to $1.7 billion in potential future development, regulatory, and sales milestones as well as royalties on future products nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the united states san francisco, april 02, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that gilead sciences has elected to extend the research term of the companies' ongoing collaboration, originally established in 2019, by an additional two years. “gilead's extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
NRIX Ratings Summary
NRIX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission